<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372283">
  <stage>Registered</stage>
  <submitdate>3/02/2017</submitdate>
  <approvaldate>27/02/2017</approvaldate>
  <actrnumber>ACTRN12617000310369</actrnumber>
  <trial_identification>
    <studytitle>Development of a method for describing lactate kinetics in ICU patients  a pilot study in healthy volunteers.</studytitle>
    <scientifictitle>Development of a method for describing lactate kinetics in ICU patients using a stable labeled 13C-lactate bolus  a pilot study in healthy volunteers.</scientifictitle>
    <utrn>U1111-1192-4875</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Intensive care patients</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Healthy volunteers will receive a peripheral venous catheter and an arterial catheter. They will then receive a bolus of 13-labelled lactate (2.7mg/kg) and blood samples will be drawn continuously during the next two hours (not more than 100ml blood will be drawn).</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Enrichment of 13-lactate. Rate of appearance and rate of disappearance of endogenous lactate will be assessed by Gas Chromatography-Mass spectrometry (GC-MS) </outcome>
      <timepoint>Samples are taken at baseline and throughout the following two hours, every other minute the first hour and every fifth minute the second hour (t=0 and at time points:  2, 4, 6,... 56, 58, 60, 65, 70, 75... 110, 115, 120)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome> Normalization of lactate levels after bolus, defined as return to baseline levels (t=0).</outcome>
      <timepoint>Samples are taken at baseline and throughout the following two hours, every other minute the first hour and every fifth minute the second hour (t=0 and at time points:  2, 4, 6,... 56, 58, 60, 65, 70, 75... 110, 115, 120)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers without ongoing mediaction</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Abnormalities on lab screening, including pregnancy test</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods>Mathematical modeling of rate of appearance / disappearance.
ANOVA for repeated measurements and student´s t-test to compare individual time points will be used for statistical analysis.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>13/01/2017</actualstartdate>
    <anticipatedenddate>31/03/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>6</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Karolinska University Hospital </primarysponsorname>
    <primarysponsoraddress>Karolinska University Hospital 
Dept of Anesthesiology and Intensive Care
K32 
141 86 Stockholm Sweden
</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Karolinska University Hospital</fundingname>
      <fundingaddress>Karolinska University Hospital
Dept of Anesthesiology and Intensive Care
K32 
141 86 Stockholm Sweden</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Karolinska Institutet</fundingname>
      <fundingaddress>CLINTEC, dept of Anesthesiology and Intensive Care
K32
141 86 Stockholm Sweden</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In order to study lactate kinetics in ICU patients with a minimally invasive technique we are performing this pilot study on healthy volunteers.
After a standard health form, medical examination and testing the fasting subjects will receive venous and arterial catheters. Base line samples are drawn and frozen. A bolus of stable isotopically labeled 13C-lactate will be given (2.7mg/kg body weight). Blood samples will be drawn at 37 time points throughout 2 hours (not more than 100ml blood al together). Samples will be analyzed at bedside analyzer and snap frozen for later analysis for relationship between 13C-labelled and normal lactate.
Subjects will monitored with ECG, pulsoximetry and blood pressure throughout the experiment.
</summary>
    <trialwebsite>No</trialwebsite>
    <publication>No</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>No</publicnotes>
    <ethicscommitee>
      <ethicname>Regional Ethics Committee Stockholm</ethicname>
      <ethicaddress>Tomtebodavägen 18A, 
FE 289
171 77 STOCKHOLM</ethicaddress>
      <ethicapprovaldate>4/05/2016</ethicapprovaldate>
      <hrec>2016/722-31/1</hrec>
      <ethicsubmitdate>31/03/2016</ethicsubmitdate>
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Jan Wernerman</name>
      <address>Karolinska University Hospital
Dept. of Anesthesiology and Intensive Care
K32
141 86 Stockholm Sweden</address>
      <phone>+46858586337</phone>
      <fax />
      <email>jan.wernerman@sll.se</email>
      <country>Sweden</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jonathan Grip</name>
      <address>Karolinska University Hospital
Dept. of Anesthesiology and Intensive Care
K32
141 86 Stockholm Sweden</address>
      <phone>+46736230906</phone>
      <fax />
      <email>jonathan.grip@ki.se</email>
      <country>Sweden</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jonathan Grip</name>
      <address>Karolinska University Hospital
Dept. of Anesthesiology and Intensive Care
K32
141 86 Stockholm Sweden</address>
      <phone>+46736230906</phone>
      <fax />
      <email>jonathan.grip@ki.se</email>
      <country>Sweden</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jonathan Grip</name>
      <address>Karolinska University Hospital
Dept. of Anesthesiology and Intensive Care
K32
141 86 Stockholm Sweden</address>
      <phone>+4673623096</phone>
      <fax />
      <email>jonathan.grip@ki.se</email>
      <country>Sweden</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>